Stockscreener 앱 받기
42.23
5.29%
2.12
전일 마감가:
$40.11
열려 있는:
$41.85
하루 거래량:
16.32M
Relative Volume:
1.42
시가총액:
$16.50B
수익:
$3.14B
순이익/손실:
$-3.36B
주가수익비율:
-4.8373
EPS:
-8.73
순현금흐름:
$-4.03B
1주 성능:
+2.97%
1개월 성능:
+6.64%
6개월 성능:
+57.05%
1년 성능:
+32.30%
1일 변동 폭
$41.20
$44.80
1주일 범위
$36.66
$45.50
52주 변동 폭
$22.28
$55.20
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
42.23 | 15.67B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
U.S. vaccine policy under RFK Jr. challenged in court (PFE) - Seeking Alpha
Earnings Scorecard: Healthcare sector shows strong top-line pulse - Seeking Alpha
Barclays starts Moderna, Inc. (MRNA) neutral as biotech outlook improves - MSN
CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot - The Cancer Letter
Moderna CEO Worries About Drug Development Overall After US FDA mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna looks outside US for growth after FDA’s flu shot refusal - whbl.com
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results - FinancialContent
Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend - FXEmpire
Moderna Reports a Narrower-Than-Expected Loss. The Stock Slips After Earnings. - Barron's
Moderna Has A Few Words For The FDA After mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Moderna: Q4 Earnings Snapshot - theheraldreview.com
Moderna Inc (MRNA) Q4 2025 Earnings Call Highlights: Strategic Cost Reductions Amidst Financial Challenges - GuruFocus
Moderna (MRNA) Faces Challenges Amid Renewed Interest in Biotech Sector - GuruFocus
Moderna Challenges FDA After Flu Shot Review Refusal, 26% Covid Drop - GuruFocus
Market movers: Moderna, Pinterest, DraftKings, Coinbase, Immunic... - Proactive financial news
Moderna's mRNA Technology Has Potential Across Vaccines, Oncology, and Rare Diseases - Morningstar
Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results, Beats Estimates By $0.68 EPS - MarketBeat
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates - The Desert Sun
Moderna Reports 4Q Revenue Of $678 Million, Projects 2026 Growth - AlphaStreet News
Moderna shares jump as company affirms growth outlook - BioPharma Dive
Moderna shares pop on strong guidance, smaller-than-expected loss - Yahoo Finance
Pink Sheet Podcast: US FDA Versus Moderna And The Changing Role Of Refuse To File Actions - Citeline News & Insights
Moderna climbs 11% after Q4 revenue beats estimates - breakingthenews.net
Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates - Nasdaq
FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’ - The Guardian
Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation - BioSpace
Moderna beats Q4 revenue estimate - BNN Bloomberg
Moderna (MRNA) Shares Rise Despite FDA Rejection of Flu Vaccine Application - GuruFocus
Moderna tops Q4 2025 EPS by 51c, beats on revenue - The Pharma Letter
Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms - Benzinga
Moderna (NASDAQ:MRNA) Trading 7.2% Higher Following Better-Than-Expected Earnings - MarketBeat
Moderna Maintains Full-Year Revenue Growth Outlook Following Fourth-Quarter Beat - marketscreener.com
Moderna Q4 Earnings Call Highlights - MarketBeat
Moderna Shares Rise After Q4 Loss Narrows, Revenue Beats Estimates - marketscreener.com
Softer-Than-Expected Inflation Sparks Rally In These 10 Stocks - Benzinga
Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, and More Movers - Barron's
Moderna Q4 2025 slides reveal strategic pivot as losses narrow, shares climb - Investing.com
Moderna Sales Beat as Covid Shot Demand Falls Less Than Expected - Bloomberg.com
Earnings call transcript: Moderna’s Q4 2025 results exceed expectations - Investing.com
Moderna Reiterates 10% Revenue-Growth Target as Covid Vaccine Demand Falls - The Wall Street Journal
Moderna Reiterates 10% Revenue-Growth Target as Covid Vaccine Demand Falls -- Update - marketscreener.com
Moderna Q4 Loss Narrows - Nasdaq
AI for investors - MLQ.ai
Moderna beats quarterly revenue estimates on resilient COVID shot sales - BNN Bloomberg
A Political Appointee Overruled FDA Scientists to Block Moderna's Flu Vaccine — and the Fallout Is Just Beginning - WebProNews
Applied Materials, Arista, Moderna, Coinbase, DraftKings, Steel Dynamics, Rivian, Roku, and More Movers - Barron's
Moderna Just Crushed Estimates While Everyone Was Looking the Other Way - 24/7 Wall St.
Moderna (MRNA) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Moderna (MRNA) Surpasses Q4 Earnings Expectations Despite Revenue Decline - GuruFocus
Moderna (MRNA) Q4 2025 Earnings Call Transcript - The Globe and Mail
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
모더나 주식 (MRNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
Dec 11 '25 |
Sale |
29.48 |
23,853 |
703,306 |
3,924 |
| Bancel Stephane | Chief Executive Officer |
Dec 11 '25 |
Option Exercise |
10.90 |
688,073 |
7,499,996 |
6,181,970 |
1.12%
0.87%
자본화:
|
볼륨(24시간):